US Patent Issued to The University of Bristol on Feb. 10 for "AAV gene therapy for treating nephrotic syndrome" (British Inventors)

ALEXANDRIA, Va., Feb. 11 -- United States Patent no. 12,544,460, issued on Feb. 10, was assigned to The University of Bristol (Bristol, Great Britain).

"AAV gene therapy for treating nephrotic syndrome" was invented by Moin Ahson Saleem-Uddin (Bristol, Great Britain) and Gavin Iain Welsh (Bristol, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides an adeno-associated virus (AAV) vector gene therapy for use in treating a monogenic form of nephrotic syndrome, wherein the AAV vector comprises a NS-associated transgene and minimal nephrin promoter NPHIS1 or podocin promoter NPHIS2."

The patent was filed on Jan. 17, 2020, under Application No. 17/422,739.

*For further in...